HUTCHMED (China) Limited
HUTCHMED (China) Limited (HMDCF) Stock Competitors & Peer Comparison
See (HMDCF) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HMDCF | $2.90 | +2.84% | 2.5B | 5.47 | $0.53 | N/A |
| IPSEY | $43.09 | -3.45% | 57B | 28.16 | $1.53 | +0.93% |
| TKPHF | $34.05 | -9.71% | 55.3B | 79.55 | $0.44 | +3.78% |
| MKKGY | $24.02 | +0.86% | 52.1B | 15.35 | $1.56 | +2.09% |
| MKGAF | $123.02 | +2.08% | 50.7B | 14.96 | $7.80 | +2.14% |
| HLNCF | $4.97 | -2.93% | 44.5B | 20.00 | $0.25 | +1.83% |
| SDZNY | $75.37 | -1.58% | 33.2B | 36.67 | $2.09 | +0.95% |
| TEVJF | $28.36 | +0.00% | 32.5B | 23.44 | $1.21 | N/A |
| SGIOF | $21.45 | +19.17% | 18.3B | 17.02 | $1.26 | +2.06% |
| TAIPY | $14.00 | +16.67% | 18.1B | 82.35 | $0.17 | N/A |
Stock Comparison
HMDCF vs IPSEY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, IPSEY has a market cap of 57B. Regarding current trading prices, HMDCF is priced at $2.90, while IPSEY trades at $43.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas IPSEY's P/E ratio is 28.16. In terms of profitability, HMDCF's ROE is +0.42%, compared to IPSEY's ROE of +0.10%. Regarding short-term risk, HMDCF is more volatile compared to IPSEY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check IPSEY's competition here
HMDCF vs TKPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TKPHF has a market cap of 55.3B. Regarding current trading prices, HMDCF is priced at $2.90, while TKPHF trades at $34.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TKPHF's P/E ratio is 79.55. In terms of profitability, HMDCF's ROE is +0.42%, compared to TKPHF's ROE of +0.02%. Regarding short-term risk, HMDCF is more volatile compared to TKPHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TKPHF's competition here
HMDCF vs MKKGY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, MKKGY has a market cap of 52.1B. Regarding current trading prices, HMDCF is priced at $2.90, while MKKGY trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas MKKGY's P/E ratio is 15.35. In terms of profitability, HMDCF's ROE is +0.42%, compared to MKKGY's ROE of +0.09%. Regarding short-term risk, HMDCF is more volatile compared to MKKGY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check MKKGY's competition here
HMDCF vs MKGAF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, MKGAF has a market cap of 50.7B. Regarding current trading prices, HMDCF is priced at $2.90, while MKGAF trades at $123.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas MKGAF's P/E ratio is 14.96. In terms of profitability, HMDCF's ROE is +0.42%, compared to MKGAF's ROE of +0.09%. Regarding short-term risk, HMDCF is more volatile compared to MKGAF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check MKGAF's competition here
HMDCF vs HLNCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HLNCF has a market cap of 44.5B. Regarding current trading prices, HMDCF is priced at $2.90, while HLNCF trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HLNCF's P/E ratio is 20.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to HLNCF's ROE of +0.09%. Regarding short-term risk, HMDCF is more volatile compared to HLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HLNCF's competition here
HMDCF vs SDZNY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SDZNY has a market cap of 33.2B. Regarding current trading prices, HMDCF is priced at $2.90, while SDZNY trades at $75.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SDZNY's P/E ratio is 36.67. In terms of profitability, HMDCF's ROE is +0.42%, compared to SDZNY's ROE of +0.08%. Regarding short-term risk, HMDCF is more volatile compared to SDZNY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SDZNY's competition here
HMDCF vs TEVJF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TEVJF has a market cap of 32.5B. Regarding current trading prices, HMDCF is priced at $2.90, while TEVJF trades at $28.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TEVJF's P/E ratio is 23.44. In terms of profitability, HMDCF's ROE is +0.42%, compared to TEVJF's ROE of +0.20%. Regarding short-term risk, HMDCF is more volatile compared to TEVJF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TEVJF's competition here
HMDCF vs SGIOF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SGIOF has a market cap of 18.3B. Regarding current trading prices, HMDCF is priced at $2.90, while SGIOF trades at $21.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SGIOF's P/E ratio is 17.02. In terms of profitability, HMDCF's ROE is +0.42%, compared to SGIOF's ROE of +0.14%. Regarding short-term risk, HMDCF is more volatile compared to SGIOF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SGIOF's competition here
HMDCF vs TAIPY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TAIPY has a market cap of 18.1B. Regarding current trading prices, HMDCF is priced at $2.90, while TAIPY trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TAIPY's P/E ratio is 82.35. In terms of profitability, HMDCF's ROE is +0.42%, compared to TAIPY's ROE of +0.02%. Regarding short-term risk, HMDCF is more volatile compared to TAIPY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TAIPY's competition here
HMDCF vs SGIOY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SGIOY has a market cap of 17.7B. Regarding current trading prices, HMDCF is priced at $2.90, while SGIOY trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SGIOY's P/E ratio is 16.51. In terms of profitability, HMDCF's ROE is +0.42%, compared to SGIOY's ROE of +0.14%. Regarding short-term risk, HMDCF is more volatile compared to SGIOY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SGIOY's competition here
HMDCF vs ESALY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, HMDCF is priced at $2.90, while ESALY trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ESALY's P/E ratio is 20.54. In terms of profitability, HMDCF's ROE is +0.42%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, HMDCF is more volatile compared to ESALY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ESALY's competition here
HMDCF vs BIOVF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, BIOVF has a market cap of 14.3B. Regarding current trading prices, HMDCF is priced at $2.90, while BIOVF trades at $41.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas BIOVF's P/E ratio is 295.14. In terms of profitability, HMDCF's ROE is +0.42%, compared to BIOVF's ROE of +0.01%. Regarding short-term risk, HMDCF is more volatile compared to BIOVF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check BIOVF's competition here
HMDCF vs IPSEF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, IPSEF has a market cap of 9.7B. Regarding current trading prices, HMDCF is priced at $2.90, while IPSEF trades at $117.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas IPSEF's P/E ratio is 18.79. In terms of profitability, HMDCF's ROE is +0.42%, compared to IPSEF's ROE of +0.12%. Regarding short-term risk, HMDCF is more volatile compared to IPSEF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check IPSEF's competition here
HMDCF vs ESALF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ESALF has a market cap of 9.3B. Regarding current trading prices, HMDCF is priced at $2.90, while ESALF trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ESALF's P/E ratio is 30.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to ESALF's ROE of +0.05%. Regarding short-term risk, HMDCF is more volatile compared to ESALF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ESALF's competition here
HMDCF vs ESAIY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ESAIY has a market cap of 8.5B. Regarding current trading prices, HMDCF is priced at $2.90, while ESAIY trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ESAIY's P/E ratio is 27.72. In terms of profitability, HMDCF's ROE is +0.42%, compared to ESAIY's ROE of +0.05%. Regarding short-term risk, HMDCF is more volatile compared to ESAIY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ESAIY's competition here
HMDCF vs SFOSF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SFOSF has a market cap of 6.2B. Regarding current trading prices, HMDCF is priced at $2.90, while SFOSF trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SFOSF's P/E ratio is 12.94. In terms of profitability, HMDCF's ROE is +0.42%, compared to SFOSF's ROE of +0.07%. Regarding short-term risk, HMDCF is more volatile compared to SFOSF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SFOSF's competition here
HMDCF vs GZPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GZPHF has a market cap of 5.9B. Regarding current trading prices, HMDCF is priced at $2.90, while GZPHF trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GZPHF's P/E ratio is 9.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to GZPHF's ROE of +0.08%. Regarding short-term risk, HMDCF is more volatile compared to GZPHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GZPHF's competition here
HMDCF vs HLUBF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HLUBF has a market cap of 5.3B. Regarding current trading prices, HMDCF is priced at $2.90, while HLUBF trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HLUBF's P/E ratio is 10.96. In terms of profitability, HMDCF's ROE is +0.42%, compared to HLUBF's ROE of +0.13%. Regarding short-term risk, HMDCF is more volatile compared to HLUBF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HLUBF's competition here
HMDCF vs DNPUF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, DNPUF has a market cap of 5.3B. Regarding current trading prices, HMDCF is priced at $2.90, while DNPUF trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas DNPUF's P/E ratio is 5.48. In terms of profitability, HMDCF's ROE is +0.42%, compared to DNPUF's ROE of +0.49%. Regarding short-term risk, HMDCF is more volatile compared to DNPUF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check DNPUF's competition here
HMDCF vs LVZPF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, LVZPF has a market cap of 5.1B. Regarding current trading prices, HMDCF is priced at $2.90, while LVZPF trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas LVZPF's P/E ratio is 12.79. In terms of profitability, HMDCF's ROE is +0.42%, compared to LVZPF's ROE of +0.15%. Regarding short-term risk, HMDCF is more volatile compared to LVZPF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check LVZPF's competition here
HMDCF vs HLBBF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HLBBF has a market cap of 4.5B. Regarding current trading prices, HMDCF is priced at $2.90, while HLBBF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HLBBF's P/E ratio is 11.18. In terms of profitability, HMDCF's ROE is +0.42%, compared to HLBBF's ROE of +0.13%. Regarding short-term risk, HMDCF is more volatile compared to HLBBF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HLBBF's competition here
HMDCF vs SMDPY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SMDPY has a market cap of 4.5B. Regarding current trading prices, HMDCF is priced at $2.90, while SMDPY trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SMDPY's P/E ratio is 4.61. In terms of profitability, HMDCF's ROE is +0.42%, compared to SMDPY's ROE of +0.49%. Regarding short-term risk, HMDCF is more volatile compared to SMDPY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SMDPY's competition here
HMDCF vs SGFEF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SGFEF has a market cap of 4.4B. Regarding current trading prices, HMDCF is priced at $2.90, while SGFEF trades at $100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SGFEF's P/E ratio is 20.66. In terms of profitability, HMDCF's ROE is +0.42%, compared to SGFEF's ROE of +0.16%. Regarding short-term risk, HMDCF is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check SGFEF's competition here
HMDCF vs HKMPY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HKMPY has a market cap of 3.6B. Regarding current trading prices, HMDCF is priced at $2.90, while HKMPY trades at $32.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HKMPY's P/E ratio is 9.11. In terms of profitability, HMDCF's ROE is +0.42%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, HMDCF is more volatile compared to HKMPY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HKMPY's competition here
HMDCF vs HKMPF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HKMPF has a market cap of 3.6B. Regarding current trading prices, HMDCF is priced at $2.90, while HKMPF trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HKMPF's P/E ratio is 9.06. In terms of profitability, HMDCF's ROE is +0.42%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, HMDCF is more volatile compared to HKMPF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HKMPF's competition here
HMDCF vs ULIHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ULIHF has a market cap of 3.5B. Regarding current trading prices, HMDCF is priced at $2.90, while ULIHF trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ULIHF's P/E ratio is 7.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to ULIHF's ROE of +0.20%. Regarding short-term risk, HMDCF is more volatile compared to ULIHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ULIHF's competition here
HMDCF vs APNHY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, APNHY has a market cap of 3.3B. Regarding current trading prices, HMDCF is priced at $2.90, while APNHY trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas APNHY's P/E ratio is -31.23. In terms of profitability, HMDCF's ROE is +0.42%, compared to APNHY's ROE of -0.02%. Regarding short-term risk, HMDCF is more volatile compared to APNHY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check APNHY's competition here
HMDCF vs LBTSF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, LBTSF has a market cap of 3.3B. Regarding current trading prices, HMDCF is priced at $2.90, while LBTSF trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas LBTSF's P/E ratio is 61.40. In terms of profitability, HMDCF's ROE is +0.42%, compared to LBTSF's ROE of +0.04%. Regarding short-term risk, HMDCF is more volatile compared to LBTSF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check LBTSF's competition here
HMDCF vs APNHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, APNHF has a market cap of 3.2B. Regarding current trading prices, HMDCF is priced at $2.90, while APNHF trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas APNHF's P/E ratio is -30.21. In terms of profitability, HMDCF's ROE is +0.42%, compared to APNHF's ROE of -0.02%. Regarding short-term risk, HMDCF is more volatile compared to APNHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check APNHF's competition here
HMDCF vs INVVY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, HMDCF is priced at $2.90, while INVVY trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas INVVY's P/E ratio is -62.42. In terms of profitability, HMDCF's ROE is +0.42%, compared to INVVY's ROE of -0.99%. Regarding short-term risk, HMDCF is more volatile compared to INVVY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check INVVY's competition here
HMDCF vs HYPMY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HYPMY has a market cap of 3B. Regarding current trading prices, HMDCF is priced at $2.90, while HYPMY trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HYPMY's P/E ratio is 11.83. In terms of profitability, HMDCF's ROE is +0.42%, compared to HYPMY's ROE of +0.10%. Regarding short-term risk, HMDCF is more volatile compared to HYPMY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HYPMY's competition here
HMDCF vs IZQVF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, HMDCF is priced at $2.90, while IZQVF trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, HMDCF's ROE is +0.42%, compared to IZQVF's ROE of -0.99%. Regarding short-term risk, HMDCF is more volatile compared to IZQVF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check IZQVF's competition here
HMDCF vs NPPNY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, NPPNY has a market cap of 2.3B. Regarding current trading prices, HMDCF is priced at $2.90, while NPPNY trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas NPPNY's P/E ratio is 11.77. In terms of profitability, HMDCF's ROE is +0.42%, compared to NPPNY's ROE of +0.12%. Regarding short-term risk, HMDCF is more volatile compared to NPPNY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check NPPNY's competition here
HMDCF vs CHSYF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CHSYF has a market cap of 2.3B. Regarding current trading prices, HMDCF is priced at $2.90, while CHSYF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CHSYF's P/E ratio is 9.31. In terms of profitability, HMDCF's ROE is +0.42%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, HMDCF is more volatile compared to CHSYF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CHSYF's competition here
HMDCF vs NPNKF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, NPNKF has a market cap of 2.2B. Regarding current trading prices, HMDCF is priced at $2.90, while NPNKF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas NPNKF's P/E ratio is 10.77. In terms of profitability, HMDCF's ROE is +0.42%, compared to NPNKF's ROE of +0.11%. Regarding short-term risk, HMDCF is more volatile compared to NPNKF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check NPNKF's competition here
HMDCF vs DMPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, DMPHF has a market cap of 2.1B. Regarding current trading prices, HMDCF is priced at $2.90, while DMPHF trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, HMDCF's ROE is +0.42%, compared to DMPHF's ROE of +0.19%. Regarding short-term risk, HMDCF is more volatile compared to DMPHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check DMPHF's competition here
HMDCF vs TSMRF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TSMRF has a market cap of 2.1B. Regarding current trading prices, HMDCF is priced at $2.90, while TSMRF trades at $28.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TSMRF's P/E ratio is 12.19. In terms of profitability, HMDCF's ROE is +0.42%, compared to TSMRF's ROE of +0.10%. Regarding short-term risk, HMDCF is more volatile compared to TSMRF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TSMRF's competition here
HMDCF vs HTSUF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HTSUF has a market cap of 2B. Regarding current trading prices, HMDCF is priced at $2.90, while HTSUF trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HTSUF's P/E ratio is 16.76. In terms of profitability, HMDCF's ROE is +0.42%, compared to HTSUF's ROE of +0.07%. Regarding short-term risk, HMDCF is more volatile compared to HTSUF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HTSUF's competition here
HMDCF vs ARSUF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ARSUF has a market cap of 2B. Regarding current trading prices, HMDCF is priced at $2.90, while ARSUF trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ARSUF's P/E ratio is 19.01. In terms of profitability, HMDCF's ROE is +0.42%, compared to ARSUF's ROE of +0.17%. Regarding short-term risk, HMDCF is more volatile compared to ARSUF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ARSUF's competition here
HMDCF vs DUTV Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, DUTV has a market cap of 1.9B. Regarding current trading prices, HMDCF is priced at $2.90, while DUTV trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas DUTV's P/E ratio is N/A. In terms of profitability, HMDCF's ROE is +0.42%, compared to DUTV's ROE of -0.04%. Regarding short-term risk, HMDCF is more volatile compared to DUTV. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check DUTV's competition here
HMDCF vs CURLF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CURLF has a market cap of 1.8B. Regarding current trading prices, HMDCF is priced at $2.90, while CURLF trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CURLF's P/E ratio is -7.25. In terms of profitability, HMDCF's ROE is +0.42%, compared to CURLF's ROE of -0.29%. Regarding short-term risk, HMDCF is more volatile compared to CURLF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CURLF's competition here
HMDCF vs SHPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SHPHF has a market cap of 1.7B. Regarding current trading prices, HMDCF is priced at $2.90, while SHPHF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SHPHF's P/E ratio is -6.22. In terms of profitability, HMDCF's ROE is +0.42%, compared to SHPHF's ROE of -0.02%. Regarding short-term risk, HMDCF is more volatile compared to SHPHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SHPHF's competition here
HMDCF vs MITPF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, HMDCF is priced at $2.90, while MITPF trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas MITPF's P/E ratio is -10.81. In terms of profitability, HMDCF's ROE is +0.42%, compared to MITPF's ROE of +4.99%. Regarding short-term risk, HMDCF is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check MITPF's competition here
HMDCF vs GTBIF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GTBIF has a market cap of 1.6B. Regarding current trading prices, HMDCF is priced at $2.90, while GTBIF trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GTBIF's P/E ratio is 13.67. In terms of profitability, HMDCF's ROE is +0.42%, compared to GTBIF's ROE of +0.06%. Regarding short-term risk, HMDCF is more volatile compared to GTBIF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GTBIF's competition here
HMDCF vs KARBF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, HMDCF is priced at $2.90, while KARBF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas KARBF's P/E ratio is 262.50. In terms of profitability, HMDCF's ROE is +0.42%, compared to KARBF's ROE of N/A. Regarding short-term risk, HMDCF is more volatile compared to KARBF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check KARBF's competition here
HMDCF vs CASBF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CASBF has a market cap of 1.4B. Regarding current trading prices, HMDCF is priced at $2.90, while CASBF trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CASBF's P/E ratio is -39.70. In terms of profitability, HMDCF's ROE is +0.42%, compared to CASBF's ROE of +0.01%. Regarding short-term risk, HMDCF is more volatile compared to CASBF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CASBF's competition here
HMDCF vs CHIZF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CHIZF has a market cap of 1.4B. Regarding current trading prices, HMDCF is priced at $2.90, while CHIZF trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CHIZF's P/E ratio is -27.34. In terms of profitability, HMDCF's ROE is +0.42%, compared to CHIZF's ROE of -0.01%. Regarding short-term risk, HMDCF is more volatile compared to CHIZF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CHIZF's competition here
HMDCF vs SWGHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SWGHF has a market cap of 1.3B. Regarding current trading prices, HMDCF is priced at $2.90, while SWGHF trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, HMDCF's ROE is +0.42%, compared to SWGHF's ROE of +0.05%. Regarding short-term risk, HMDCF is more volatile compared to SWGHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SWGHF's competition here
HMDCF vs KSPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, KSPHF has a market cap of 1.3B. Regarding current trading prices, HMDCF is priced at $2.90, while KSPHF trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas KSPHF's P/E ratio is 14.15. In terms of profitability, HMDCF's ROE is +0.42%, compared to KSPHF's ROE of +0.07%. Regarding short-term risk, HMDCF is more volatile compared to KSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check KSPHF's competition here
HMDCF vs EVOTF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, EVOTF has a market cap of 1.3B. Regarding current trading prices, HMDCF is priced at $2.90, while EVOTF trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas EVOTF's P/E ratio is -6.84. In terms of profitability, HMDCF's ROE is +0.42%, compared to EVOTF's ROE of -0.18%. Regarding short-term risk, HMDCF is more volatile compared to EVOTF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check EVOTF's competition here
HMDCF vs TWAPF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TWAPF has a market cap of 1.2B. Regarding current trading prices, HMDCF is priced at $2.90, while TWAPF trades at $25.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TWAPF's P/E ratio is 9.45. In terms of profitability, HMDCF's ROE is +0.42%, compared to TWAPF's ROE of +0.12%. Regarding short-term risk, HMDCF is more volatile compared to TWAPF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TWAPF's competition here
HMDCF vs TCNNF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TCNNF has a market cap of 1.2B. Regarding current trading prices, HMDCF is priced at $2.90, while TCNNF trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TCNNF's P/E ratio is -10.84. In terms of profitability, HMDCF's ROE is +0.42%, compared to TCNNF's ROE of -0.10%. Regarding short-term risk, HMDCF is more volatile compared to TCNNF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TCNNF's competition here
HMDCF vs LJUIF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, LJUIF has a market cap of 1.2B. Regarding current trading prices, HMDCF is priced at $2.90, while LJUIF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas LJUIF's P/E ratio is 13.42. In terms of profitability, HMDCF's ROE is +0.42%, compared to LJUIF's ROE of +0.09%. Regarding short-term risk, HMDCF is less volatile compared to LJUIF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check LJUIF's competition here
HMDCF vs BIOGY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, BIOGY has a market cap of 1.1B. Regarding current trading prices, HMDCF is priced at $2.90, while BIOGY trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas BIOGY's P/E ratio is 31.43. In terms of profitability, HMDCF's ROE is +0.42%, compared to BIOGY's ROE of +0.24%. Regarding short-term risk, HMDCF is more volatile compared to BIOGY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check BIOGY's competition here
HMDCF vs SHEZF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SHEZF has a market cap of 1.1B. Regarding current trading prices, HMDCF is priced at $2.90, while SHEZF trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SHEZF's P/E ratio is -36.03. In terms of profitability, HMDCF's ROE is +0.42%, compared to SHEZF's ROE of +0.03%. Regarding short-term risk, HMDCF is more volatile compared to SHEZF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SHEZF's competition here
HMDCF vs KKPCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, KKPCF has a market cap of 1B. Regarding current trading prices, HMDCF is priced at $2.90, while KKPCF trades at $26.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas KKPCF's P/E ratio is 297.56. In terms of profitability, HMDCF's ROE is +0.42%, compared to KKPCF's ROE of -0.03%. Regarding short-term risk, HMDCF is more volatile compared to KKPCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check KKPCF's competition here
HMDCF vs GNMLF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GNMLF has a market cap of 925.1M. Regarding current trading prices, HMDCF is priced at $2.90, while GNMLF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GNMLF's P/E ratio is 10.56. In terms of profitability, HMDCF's ROE is +0.42%, compared to GNMLF's ROE of +0.11%. Regarding short-term risk, HMDCF is more volatile compared to GNMLF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GNMLF's competition here
HMDCF vs CSWYF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CSWYF has a market cap of 815.8M. Regarding current trading prices, HMDCF is priced at $2.90, while CSWYF trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CSWYF's P/E ratio is 5.14. In terms of profitability, HMDCF's ROE is +0.42%, compared to CSWYF's ROE of +0.20%. Regarding short-term risk, HMDCF is more volatile compared to CSWYF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CSWYF's competition here
HMDCF vs NIKA Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, NIKA has a market cap of 785.6M. Regarding current trading prices, HMDCF is priced at $2.90, while NIKA trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas NIKA's P/E ratio is N/A. In terms of profitability, HMDCF's ROE is +0.42%, compared to NIKA's ROE of +0.21%. Regarding short-term risk, HMDCF is more volatile compared to NIKA. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check NIKA's competition here
HMDCF vs TRXPF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, HMDCF is priced at $2.90, while TRXPF trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, HMDCF's ROE is +0.42%, compared to TRXPF's ROE of +0.04%. Regarding short-term risk, HMDCF is more volatile compared to TRXPF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TRXPF's competition here
HMDCF vs YIHCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, YIHCF has a market cap of 643.1M. Regarding current trading prices, HMDCF is priced at $2.90, while YIHCF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to YIHCF's ROE of +0.06%. Regarding short-term risk, HMDCF is more volatile compared to YIHCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check YIHCF's competition here
HMDCF vs AIHLF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, AIHLF has a market cap of 624.3M. Regarding current trading prices, HMDCF is priced at $2.90, while AIHLF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas AIHLF's P/E ratio is 10.94. In terms of profitability, HMDCF's ROE is +0.42%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, HMDCF is more volatile compared to AIHLF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check AIHLF's competition here
HMDCF vs TRSSF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, HMDCF is priced at $2.90, while TRSSF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, HMDCF's ROE is +0.42%, compared to TRSSF's ROE of -0.68%. Regarding short-term risk, HMDCF is more volatile compared to TRSSF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check TRSSF's competition here
HMDCF vs GLASF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GLASF has a market cap of 590.1M. Regarding current trading prices, HMDCF is priced at $2.90, while GLASF trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GLASF's P/E ratio is -36.36. In terms of profitability, HMDCF's ROE is +0.42%, compared to GLASF's ROE of -0.01%. Regarding short-term risk, HMDCF is more volatile compared to GLASF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GLASF's competition here
HMDCF vs PKBFF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, PKBFF has a market cap of 544.7M. Regarding current trading prices, HMDCF is priced at $2.90, while PKBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas PKBFF's P/E ratio is N/A. In terms of profitability, HMDCF's ROE is +0.42%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, HMDCF is more volatile compared to PKBFF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check PKBFF's competition here
HMDCF vs CCHWF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, HMDCF is priced at $2.90, while CCHWF trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, HMDCF's ROE is +0.42%, compared to CCHWF's ROE of +0.42%. Regarding short-term risk, HMDCF is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check CCHWF's competition here
HMDCF vs BOIRF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, BOIRF has a market cap of 520.9M. Regarding current trading prices, HMDCF is priced at $2.90, while BOIRF trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas BOIRF's P/E ratio is 22.73. In terms of profitability, HMDCF's ROE is +0.42%, compared to BOIRF's ROE of +0.05%. Regarding short-term risk, HMDCF is more volatile compared to BOIRF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check BOIRF's competition here
HMDCF vs AGYTF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, AGYTF has a market cap of 504.6M. Regarding current trading prices, HMDCF is priced at $2.90, while AGYTF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas AGYTF's P/E ratio is -11.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to AGYTF's ROE of +1.75%. Regarding short-term risk, HMDCF is more volatile compared to AGYTF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check AGYTF's competition here
HMDCF vs KHTRF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, KHTRF has a market cap of 467M. Regarding current trading prices, HMDCF is priced at $2.90, while KHTRF trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas KHTRF's P/E ratio is -155.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to KHTRF's ROE of -0.01%. Regarding short-term risk, HMDCF is more volatile compared to KHTRF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check KHTRF's competition here
HMDCF vs PEXXF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, HMDCF is priced at $2.90, while PEXXF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to PEXXF's ROE of N/A. Regarding short-term risk, HMDCF is more volatile compared to PEXXF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check PEXXF's competition here
HMDCF vs SWDCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SWDCF has a market cap of 439.2M. Regarding current trading prices, HMDCF is priced at $2.90, while SWDCF trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SWDCF's P/E ratio is 68.69. In terms of profitability, HMDCF's ROE is +0.42%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, HMDCF is more volatile compared to SWDCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SWDCF's competition here
HMDCF vs VRNOF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, VRNOF has a market cap of 434.2M. Regarding current trading prices, HMDCF is priced at $2.90, while VRNOF trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas VRNOF's P/E ratio is -1.21. In terms of profitability, HMDCF's ROE is +0.42%, compared to VRNOF's ROE of -0.30%. Regarding short-term risk, HMDCF is more volatile compared to VRNOF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check VRNOF's competition here
HMDCF vs HUMDF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HUMDF has a market cap of 405.4M. Regarding current trading prices, HMDCF is priced at $2.90, while HUMDF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HUMDF's P/E ratio is 2.57. In terms of profitability, HMDCF's ROE is +0.42%, compared to HUMDF's ROE of +2.33%. Regarding short-term risk, HMDCF is more volatile compared to HUMDF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HUMDF's competition here
HMDCF vs ELTP Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ELTP has a market cap of 403.9M. Regarding current trading prices, HMDCF is priced at $2.90, while ELTP trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ELTP's P/E ratio is 9.38. In terms of profitability, HMDCF's ROE is +0.42%, compared to ELTP's ROE of +0.71%. Regarding short-term risk, HMDCF is more volatile compared to ELTP. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ELTP's competition here
HMDCF vs CRLBF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CRLBF has a market cap of 331.2M. Regarding current trading prices, HMDCF is priced at $2.90, while CRLBF trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CRLBF's P/E ratio is -2.54. In terms of profitability, HMDCF's ROE is +0.42%, compared to CRLBF's ROE of -0.33%. Regarding short-term risk, HMDCF is more volatile compared to CRLBF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CRLBF's competition here
HMDCF vs CPHRF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CPHRF has a market cap of 306M. Regarding current trading prices, HMDCF is priced at $2.90, while CPHRF trades at $12.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CPHRF's P/E ratio is 11.49. In terms of profitability, HMDCF's ROE is +0.42%, compared to CPHRF's ROE of +0.24%. Regarding short-term risk, HMDCF is more volatile compared to CPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CPHRF's competition here
HMDCF vs BHCCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, BHCCF has a market cap of 225.1M. Regarding current trading prices, HMDCF is priced at $2.90, while BHCCF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, HMDCF's ROE is +0.42%, compared to BHCCF's ROE of +0.23%. Regarding short-term risk, HMDCF is more volatile compared to BHCCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check BHCCF's competition here
HMDCF vs PLNHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, HMDCF is priced at $2.90, while PLNHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, HMDCF's ROE is +0.42%, compared to PLNHF's ROE of -0.94%. Regarding short-term risk, HMDCF is more volatile compared to PLNHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check PLNHF's competition here
HMDCF vs PHCUF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, PHCUF has a market cap of 186.2M. Regarding current trading prices, HMDCF is priced at $2.90, while PHCUF trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas PHCUF's P/E ratio is -700.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to PHCUF's ROE of -0.00%. Regarding short-term risk, HMDCF is more volatile compared to PHCUF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check PHCUF's competition here
HMDCF vs SHIEF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, SHIEF has a market cap of 150.9M. Regarding current trading prices, HMDCF is priced at $2.90, while SHIEF trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas SHIEF's P/E ratio is -7.06. In terms of profitability, HMDCF's ROE is +0.42%, compared to SHIEF's ROE of +1.40%. Regarding short-term risk, HMDCF is more volatile compared to SHIEF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check SHIEF's competition here
HMDCF vs COPHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, HMDCF is priced at $2.90, while COPHF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas COPHF's P/E ratio is -0.02. In terms of profitability, HMDCF's ROE is +0.42%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, HMDCF is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check COPHF's competition here
HMDCF vs LOVFF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, LOVFF has a market cap of 130.3M. Regarding current trading prices, HMDCF is priced at $2.90, while LOVFF trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas LOVFF's P/E ratio is 15.11. In terms of profitability, HMDCF's ROE is +0.42%, compared to LOVFF's ROE of +0.12%. Regarding short-term risk, HMDCF is more volatile compared to LOVFF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check LOVFF's competition here
HMDCF vs BIOYF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, BIOYF has a market cap of 129M. Regarding current trading prices, HMDCF is priced at $2.90, while BIOYF trades at $11.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas BIOYF's P/E ratio is 20.44. In terms of profitability, HMDCF's ROE is +0.42%, compared to BIOYF's ROE of +0.23%. Regarding short-term risk, HMDCF is more volatile compared to BIOYF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check BIOYF's competition here
HMDCF vs CBWTF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CBWTF has a market cap of 127M. Regarding current trading prices, HMDCF is priced at $2.90, while CBWTF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CBWTF's P/E ratio is 3.14. In terms of profitability, HMDCF's ROE is +0.42%, compared to CBWTF's ROE of +0.29%. Regarding short-term risk, HMDCF is more volatile compared to CBWTF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CBWTF's competition here
HMDCF vs NWPN Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, HMDCF is priced at $2.90, while NWPN trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas NWPN's P/E ratio is -0.04. In terms of profitability, HMDCF's ROE is +0.42%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, HMDCF is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check NWPN's competition here
HMDCF vs CWBHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CWBHF has a market cap of 111.6M. Regarding current trading prices, HMDCF is priced at $2.90, while CWBHF trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CWBHF's P/E ratio is -5.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to CWBHF's ROE of -1.20%. Regarding short-term risk, HMDCF is more volatile compared to CWBHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CWBHF's competition here
HMDCF vs LPCUF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, LPCUF has a market cap of 110.8M. Regarding current trading prices, HMDCF is priced at $2.90, while LPCUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas LPCUF's P/E ratio is 9.41. In terms of profitability, HMDCF's ROE is +0.42%, compared to LPCUF's ROE of +0.04%. Regarding short-term risk, HMDCF is more volatile compared to LPCUF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check LPCUF's competition here
HMDCF vs CNVCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, HMDCF is priced at $2.90, while CNVCF trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to CNVCF's ROE of +1.21%. Regarding short-term risk, HMDCF is more volatile compared to CNVCF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check CNVCF's competition here
HMDCF vs HLTRF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, HLTRF has a market cap of 107.6M. Regarding current trading prices, HMDCF is priced at $2.90, while HLTRF trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas HLTRF's P/E ratio is -8.82. In terms of profitability, HMDCF's ROE is +0.42%, compared to HLTRF's ROE of -0.19%. Regarding short-term risk, HMDCF is more volatile compared to HLTRF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check HLTRF's competition here
HMDCF vs AAWH Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, AAWH has a market cap of 103.1M. Regarding current trading prices, HMDCF is priced at $2.90, while AAWH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas AAWH's P/E ratio is -0.88. In terms of profitability, HMDCF's ROE is +0.42%, compared to AAWH's ROE of -14.10%. Regarding short-term risk, HMDCF is more volatile compared to AAWH. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check AAWH's competition here
HMDCF vs ORXOF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ORXOF has a market cap of 100.6M. Regarding current trading prices, HMDCF is priced at $2.90, while ORXOF trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ORXOF's P/E ratio is -2.34. In terms of profitability, HMDCF's ROE is +0.42%, compared to ORXOF's ROE of +5.65%. Regarding short-term risk, HMDCF is more volatile compared to ORXOF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ORXOF's competition here
HMDCF vs ORXOY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ORXOY has a market cap of 97.2M. Regarding current trading prices, HMDCF is priced at $2.90, while ORXOY trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ORXOY's P/E ratio is -2.26. In terms of profitability, HMDCF's ROE is +0.42%, compared to ORXOY's ROE of +5.65%. Regarding short-term risk, HMDCF is more volatile compared to ORXOY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check ORXOY's competition here
HMDCF vs ABSCF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, ABSCF has a market cap of 96M. Regarding current trading prices, HMDCF is priced at $2.90, while ABSCF trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas ABSCF's P/E ratio is -8.53. In terms of profitability, HMDCF's ROE is +0.42%, compared to ABSCF's ROE of +0.33%. Regarding short-term risk, HMDCF is less volatile compared to ABSCF. This indicates potentially lower risk in terms of short-term price fluctuations for HMDCF.Check ABSCF's competition here
HMDCF vs JUSHF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, JUSHF has a market cap of 92.6M. Regarding current trading prices, HMDCF is priced at $2.90, while JUSHF trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas JUSHF's P/E ratio is -1.43. In terms of profitability, HMDCF's ROE is +0.42%, compared to JUSHF's ROE of +0.89%. Regarding short-term risk, HMDCF is more volatile compared to JUSHF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check JUSHF's competition here
HMDCF vs MEDXF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, MEDXF has a market cap of 77.5M. Regarding current trading prices, HMDCF is priced at $2.90, while MEDXF trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas MEDXF's P/E ratio is -120.00. In terms of profitability, HMDCF's ROE is +0.42%, compared to MEDXF's ROE of -0.01%. Regarding short-term risk, HMDCF is more volatile compared to MEDXF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check MEDXF's competition here
HMDCF vs EOFBY Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, HMDCF is priced at $2.90, while EOFBY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, HMDCF's ROE is +0.42%, compared to EOFBY's ROE of -0.77%. Regarding short-term risk, HMDCF is more volatile compared to EOFBY. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check EOFBY's competition here
HMDCF vs GRUSF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GRUSF has a market cap of 72.6M. Regarding current trading prices, HMDCF is priced at $2.90, while GRUSF trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GRUSF's P/E ratio is 9.70. In terms of profitability, HMDCF's ROE is +0.42%, compared to GRUSF's ROE of +0.28%. Regarding short-term risk, HMDCF is more volatile compared to GRUSF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GRUSF's competition here
HMDCF vs GDNSF Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, GDNSF has a market cap of 61M. Regarding current trading prices, HMDCF is priced at $2.90, while GDNSF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas GDNSF's P/E ratio is -2.66. In terms of profitability, HMDCF's ROE is +0.42%, compared to GDNSF's ROE of -0.69%. Regarding short-term risk, HMDCF is more volatile compared to GDNSF. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check GDNSF's competition here
HMDCF vs PLNH Comparison March 2026
HMDCF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HMDCF stands at 2.5B. In comparison, PLNH has a market cap of 50.3M. Regarding current trading prices, HMDCF is priced at $2.90, while PLNH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HMDCF currently has a P/E ratio of 5.47, whereas PLNH's P/E ratio is -0.59. In terms of profitability, HMDCF's ROE is +0.42%, compared to PLNH's ROE of -0.91%. Regarding short-term risk, HMDCF is more volatile compared to PLNH. This indicates potentially higher risk in terms of short-term price fluctuations for HMDCF.Check PLNH's competition here